The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Abstract
PURPOSE AND METHODS: A prospective, randomized, multicenter phase III trial was performed to investigate the feasibility of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy in elderly patients ( > or = 60 years) with advanced non-Hodgkin's lymphoma (NHL) of intermediate- and high-grade malignancy, and to compare the tolerance and efficacy of doxorubicin versus mitoxantrone (CHOP v CNOP). RESULTS: Of 157 enrolled patients, 148 were eligible and 145 were assessable for response. Thirty-one percent of CNOP and 45% of CHOP patients completed six cycles without dose reduction. The cumulative normalized dose-intensity (NDI) was 92% with CHOP and 90% with CNOP after six cycles. The overall complete response (CR) rates were 49% and 31% in CHOP- and CNOP-treated patients, respectively (P = .03). Survival with CNOP was significantly worse as compared with CHOP (P = .03). Lymphoma-specific survival was significantly better in CHOP-treated patients (P = .034) At 3 years, 42% of CHOP and 26% of CNOP patients were alive. Additional unfavorable prognostic factors at diagnosis were high serum lactate dehydrogenase (LDH) level, bulky mass, and low performance status, but not age. The median disease-free intervals of complete responders were 27 (CHOP) and 15 (CNOP) months, respectively. Considering the complete group of patients, at 3 years 17% of CHOP and 13% of CNOP patients were alive and disease-free (P = .12). Common toxicity criteria (CTC) grade > or = 2 with CNOP and CHOP was not different. CONCLUSION: CHOP is well tolerated in elderly patients with advanced intermediate- or high-grade NHL and its NDI is not seriously impaired. Treatment with CHOP (doxorubicin) results in better CR and survival rates than CNOP (mitoxantrone). CHOP should be recommended for elderly patients with high-risk NHL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264
A Southwest Oncology Group study
Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773
MACOP-B Chemotherapy for the Treatment of Diffuse Large-Cell Lymphoma
KLIMO, P., & CONNORS, J. M. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-5-596 · Cited by 664
Treatment of Non-Hodgkin's Lymphoma
Wood, A. J. J., & Armitage, J. O. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281409 · Cited by 376
Dixon, D. O., Neilan, B., Jones, S. E., Lipschitz, D. A., Miller, T. P., Grozea, P. N., & Wilson, H. E. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.3.295 · Cited by 360
Skarin, A. T., Canellos, G. P., Rosenthal, D. S., Case, D. C., MacIntyre, J. M., Pinkus, G. S., Moloney, W. C., & Frei, E. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.2.91 · Cited by 334
Gordon, L. I., Harrington, D., Andersen, J., Colgan, J., Glick, J., Neiman, R., Mann, R., Resnick, G. D., Barcos, M., Gottlieb, A., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211053271903 · Cited by 325
SHIPP, M. A., HARRINGTON, D. P., KLATT, M. M., JOCHELSON, M. S., PINKUS, G. S., MARSHALL, J. L., ROSENTHAL, D. S., SKARIN, A. T., & CANELLOS, G. P. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-6-757 · Cited by 277
Cited by
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Management of Cancer in the Older Person: A Practical Approach
Balducci, L., & Extermann, M. (2000) · The Oncologist · doi:10.1634/theoncologist.5-3-224 · Cited by 939
Mounier, N. (2003) · Blood · doi:10.1182/blood-2002-11-3442 · Cited by 513
EORTC elderly task force position paper: Approach to the older cancer patient
Pallis, A. G., Fortpied, C., Wedding, U., Van Nes, M. C., Penninckx, B., Ring, A., Lacombe, D., Monfardini, S., Scalliet, P., & Wildiers, H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.022 · Cited by 340
Metadata
- Authors
- Sonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H., Mulder, A., van Reijswoud, I., Hop, W., & Lowenberg, B.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-10
- Volume
- 13
- Issue
- 10
- Pages
- 2530-2539
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1924320258
- Cited by
- 280
- References
- 14
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. https://app.cochat.ai/papers/10.1200/jco.1995.13.10.2530
- The paper
- Sonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H., Mulder, A., van Reijswoud, I., Hop, W., & Lowenberg, B. (1995). Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1995.13.10.2530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
